Regeneron Pharmaceuticals

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

Retrieved on: 
Tuesday, March 21, 2023
Amgen, DNA, Novartis Institute for Tropical Diseases, Drug development, Icahn School of Medicine at Mount Sinai, Regeneron Pharmaceuticals, CSO, Indian Institute of Science Education and Research, Thiruvananthapuram, Biotechnology, Howard Hughes Medical Institute, Research, Mount Sinai, Biomedical Research, Neuroscience, DSM-IV codes, Acquisition, Novartis, Patient, Hematology, Drug discovery, Cadent, Therapy, Stanley Center for Psychiatric Research at Broad Institute, Genome, Pharmaceutical industry, Beam, Sangamo Therapeutics

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO).

Key Points: 
  • CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D., has been appointed as chief scientific officer (CSO).
  • Dr. Shanker is a scientific leader with more than 20 years of drug development experience as well as experience with novel genetic medicine modalities.
  • Dr. Shanker will report to Giuseppe Ciaramella, Ph.D., president of Beam, who has broad oversight of Beam’s research, manufacturing, regulatory, quality and pharmaceutical sciences organizations.
  • “We are thrilled to welcome Gopi to the Beam team during this exciting time as we advance our diverse clinical and earlier-stage pipeline of base editing programs,” said Dr. Ciaramella.

Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

Retrieved on: 
Tuesday, March 21, 2023
Inflammation, Skin infection, Siliceous ooze, Civil service commission, Regeneron Pharmaceuticals, Parent, Overalls, Quality of life, Atopic dermatitis, Arthralgia, GPER, TCS, Pain, Heart, European Commission, Patient, Risk, Child, Biological soil crust, European, International development, Growth, Infant, Immunology, Ageing, MPH, Conjunctivitis, EC, Red, Human, Eosinophilia, Skin, Caregiver, Safety, Conditional sentence, Disease, Pharmaceutical industry, Vaccine, Medical imaging, Copper, EU, Dupilumab, Sanofi

TARRYTOWN, N.Y. and PARIS, March 21, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent® (dupilumab) in the European Union (EU) to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy. With this approval, Dupixent is the first and only targeted medicine indicated to treat these young children in Europe and the U.S.

Key Points: 
  • “I’ve personally witnessed how this chronic skin disease can disrupt the lives of entire families when left uncontrolled.
  • Between 85% and 90% of patients first develop symptoms before 5 years of age, which can often continue through adulthood.
  • Severe atopic dermatitis may also significantly impact the quality of life of young children and their caregivers.
  • “Too often the parents and caregivers of children with severe atopic dermatitis are left desperate for new treatments to manage this chronic disease.

Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis

Retrieved on: 
Saturday, March 18, 2023
American Academy of Dermatology, Oregon Health and Science University Center for Women's Health, Clinical trial, Quality of life, American Academy, Atopic dermatitis, Regeneron Pharmaceuticals, Patient, AAD, Annual general meeting, Itch, Human, Skin, Vaccine, Pharmaceutical industry, Dupilumab, Sanofi

TARRYTOWN, N.Y. and PARIS, March 18, 2023 (GLOBE NEWSWIRE) --  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis. The trial, the first evaluating a biologic for this difficult-to-treat population, met its primary and key secondary endpoints. The results were featured in a late-breaking session, one of more than 20 Dupixent scientific presentations, at the American Academy of Dermatology (AAD) 2023 Annual Meeting.

Key Points: 
  • The trial, the first evaluating a biologic for this difficult-to-treat population, met its primary and key secondary endpoints.
  • The results were featured in a late-breaking session, one of more than 20 Dupixent scientific presentations, at the American Academy of Dermatology (AAD) 2023 Annual Meeting.
  • There were significant improvements in measures of hand and foot skin pain, sleep, and hand eczema-related quality of life.
  • The trial demonstrated similar safety results to the known safety profile of Dupixent in atopic dermatitis.

Comera Life Sciences Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

Retrieved on: 
Thursday, March 16, 2023
Research, SQ, Conference, Drug development, Quality of life, Inflammatory bowel disease, IBD, Caffeine, Ulcerative colitis, Half-life, Partnership, Biotechnology, Mab, Ipilimumab, Science, Patient, Toxicity, Animal, Regeneron Pharmaceuticals, Excipient, Safety, CMRA, IV, Pharmaceutical industry, Management, Cryptocurrency, Airline

WOBURN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

Key Points: 
  • “During 2022, Comera generated significant momentum, strengthening of the Company’s capabilities, team, proprietary pipeline, and executing pharmaceutical partnerships to drive value for Comera shareholders and our partners.
  • These accomplishments have positioned Comera to achieve substantial progress across our business,” said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera.
  • Comera had $2.0 million in cash, cash equivalents, and restricted cash at December 31, 2022.
  • R&D expenses totaled $1.7 million for the year-ended December 31, 2022, compared to $1.8 million for the same period in 2021.

Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease

Retrieved on: 
Wednesday, March 15, 2023
Research, Nobel Prize in Chemistry, Machine learning, Society, Regeneron Science Talent Search, Trustee, Climate change, Risk, Physics, Injury, Software, School, Cell, Creativity, Traumatic brain injury, Brain damage, Semantics, Calculus, Sidhu, Algorithm, Human, National Medal, Student, Nobel Prize, Diagnosis, Society for Science, Science News, Weather, Language, Thought, Suicide, Kawasaki disease, RNA, Intelligence, Culture, Stroke, Caterpillar, Traffic barrier, ARD International Music Competition, Pharmaceutical industry, Birth control, Management, STEM, Chemistry, Regeneron Pharmaceuticals, T3, Science

The competition, now in its 82nd year, celebrates and rewards young scientists focused on a wide range of scientific topics.

Key Points: 
  • The competition, now in its 82nd year, celebrates and rewards young scientists focused on a wide range of scientific topics.
  • “Congratulations to the winners of the Regeneron Science Talent Search 2023,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News.
  • “My experiences participating in the Science Talent Search changed my life, helping convince me to devote my life to trying to use science to cure disease.
  • In total, Regeneron awarded $3.1 million in prizes this year, including $2,000 to each of the top scholars and their schools.

Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

Retrieved on: 
Tuesday, March 14, 2023
Research, Spanish Agency of Medicines and Medical Devices, Sale, Clinical trial, Genetic distance, Medication, Brain, AEMPS, Good laboratory practice, CTA, ARO, Cisplatin, State Administrative Expenses, AAV, Ear, Development, Administration, Medicines and Healthcare products Regulatory Agency, Patient, MHRA, Midwinter, FDA, GJB2, Regeneron Pharmaceuticals, Medical device, Health care, Hearing, Investigational New Drug, Therapy, IND, Congenital hearing loss, Pharmaceutical industry, Otorhinolaryngology, Decibel

BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.
  • Board of Directors Update: In October 2022, Decibel announced the appointment of Kevin F. McLaughlin to its Board of Directors.
  • Fourth Quarter and Full Year 2022 Financial Results:
    Cash Position: As of December 31, 2022, cash, cash equivalents and available-for-sale securities were $104.6 million, compared to $162.3 million as of December 31, 2021.
  • General and administrative expenses were $23.6 million for the full year 2022, compared to $20.4 million for the full year 2021.

Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, March 15, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Cancer, Chemistry, Ongo, ACET, Bio, Sale, CR, CD20, Exercise, Regulation of tobacco by the U.S. Food and Drug Administration, R, NHL, CAR, Research and development, Administration, Patient, SITC, ChromeOS, Regeneron Pharmaceuticals, FDA, ORR, Design, Safety, Food, ISCT, IND, CDMO, Pharmaceutical industry, Vaccine, Cryptocurrency

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2022.
  • Enrollment in the trial is currently ongoing to provide additional durability data and further support the recommended Phase 2 dose.
  • In November 2022, Adicet announced the appointment of Dr. Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer.
  • In the fourth quarter of 2022, Adicet’s new in-house manufacturing capabilities in its Redwood City facility became operational.

Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease

Retrieved on: 
Wednesday, March 15, 2023
Research, Nobel Prize in Chemistry, Machine learning, Society, Regeneron Science Talent Search, Trustee, Climate change, Risk, Injury, Physics, Software, School, Cell, Creativity, Traumatic brain injury, Brain damage, Semantics, Patient, Calculus, Sidhu, Algorithm, Human, National Medal, Student, Nobel Prize, Diagnosis, Society for Science, Science News, Weather, Language, Thought, Suicide, Kawasaki disease, RNA, Intelligence, Culture, Stroke, Caterpillar, Traffic barrier, ARD International Music Competition, Pharmaceutical industry, Birth control, Management, STEM, Chemistry, Regeneron Pharmaceuticals, T3, Science

TARRYTOWN, N.Y. and WASHINGTON, March 14, 2023 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Neel Moudgal, 17, of Saline, Mich., won the top $250,000 award in the 2023 Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.

Key Points: 
  • The competition, now in its 82nd year, celebrates and rewards young scientists focused on a wide range of scientific topics.
  • "Congratulations to the winners of the Regeneron Science Talent Search 2023," said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News.
  • The Regeneron Science Talent Search empowers young people who are passionate about innovation and using scientific discovery to contribute to improving our world.
  • In total, Regeneron awarded $3.1 million in prizes this year, including $2,000 to each of the top scholars and their schools.

Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review

Retrieved on: 
Tuesday, March 7, 2023
Omalizumab, Swelling, Quality of life, FDA, Cell, Skin, Ageing, CSU, Safety, Regeneron Pharmaceuticals, Face, Disease, Hives, Angioedema, Extrapyramidal system, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Food, Itch, Pharmaceutical industry, Sanofi

CSU is an inflammatory skin condition driven in part by type 2 inflammation, which causes sudden and debilitating hives and swelling on the skin.

Key Points: 
  • CSU is an inflammatory skin condition driven in part by type 2 inflammation, which causes sudden and debilitating hives and swelling on the skin.
  • Swelling, called angioedema, may occur most commonly on the face, hands and feet, but can also affect the throat and upper airways.
  • CSU is typically treated with H1 antihistamines, medicines that target histamine-1 receptors on cells to control symptoms of urticaria.
  • However, the disease remains uncontrolled in up to 50% of patients, who are left with limited alternative treatment options.

Roche receives FDA approval of label expansion for VENTANA PD-L1 (SP263) Assay to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo

Retrieved on: 
Monday, March 6, 2023
PD-1, Physician, Cemiplimab, Diagnosis, Lung cancer, Regeneron Pharmaceuticals, Medicine, RO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ROG, Patient, NSCLC, Phase, Food, Immunotherapy, PD-L1, FDA, Pharmaceutical industry, Nursing

This additional approval will allow more patients with locally advanced and metastatic NSCLC broader access to the immunotherapy Libtayo.

Key Points: 
  • This additional approval will allow more patients with locally advanced and metastatic NSCLC broader access to the immunotherapy Libtayo.
  • PD-L1 testing provides clinicians with essential information that helps guide clinical decision making and improve patient outcomes.
  • "This approval helps physicians make more confident treatment decisions by  identifying patients with tumours that may respond to the immunotherapy Libtayo."
  • Every year, more than 2.2 million people are diagnosed with lung cancer globally and up to 85 percent of these cases are NSCLC.3,4